Literature DB >> 7475548

Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor.

A K Kakkar1, N DeRuvo, V Chinswangwatanakul, S Tebbutt, R C Williamson.   

Abstract

Thromboembolic complications are common in patients with malignant disease. We studied the activation of coagulation in 106 patients with solid tumours and 72 healthy volunteers by measuring plasma levels of tissue factor, factor VIIa, factor XIIa, thrombin-antithrombin complex, and prothrombin fragments 1 + 2. Tissue factor was 67% higher in cancer patients (median 582 vs 349 pg/mL, p = 0.0006) and factor VIIa was 46% higher (100 vs 69 mU/mL, p = 0.0002), indicating extrinsic pathway activation. Modest activation of the intrinsic pathway (elevated factor XIIa) was seen only in patients with advanced disease or those receiving chemotherapy. Excess thrombin generation was manifested by elevations in thrombin-antithrombin complex and prothrombin fragments 1 + 2. Tissue factor pathway is clearly implicated in the hypercoagulable state of cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7475548     DOI: 10.1016/s0140-6736(95)91690-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  28 in total

1.  Antithrombotic therapy in cancer.

Authors:  A K Kakkar; R C Williamson
Journal:  BMJ       Date:  1999-06-12

Review 2.  Tissue factor and thrombosis: The clot starts here.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Thromb Haemost       Date:  2010-06-10       Impact factor: 5.249

Review 3.  Thromboembolic disease in cancer patients.

Authors:  Nadia Hindi; Nazaret Cordero; Enrique Espinosa
Journal:  Support Care Cancer       Date:  2013-02-21       Impact factor: 3.603

Review 4.  Pathogenesis of thrombosis in patients with malignancy.

Authors:  A Falanga; M B Donati
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 5.  Cardiopulmonary bypass in patients with pre-existing coagulopathy.

Authors:  William DeBois; Junli Liu; Leonard Lee; Leonard Girardi; Wilson Ko; Anthony Tortolani; Karl Krieger; O Wayne Isom
Journal:  J Extra Corpor Technol       Date:  2005-03

6.  Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells.

Authors:  Dalila Darmoul; Valérie Gratio; Hélène Devaud; Thérèse Lehy; Marc Laburthe
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

7.  Statins, aspirin and risk of venous thromboembolic events in breast cancer patients.

Authors:  Ayelet Shai; Hedy S Rennert; Ofer Lavie; Muona Ballan-Haj; Arie Bitterman; Mariana Steiner; Shoshana Keren; Gad Rennert
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

8.  Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas.

Authors:  Mark Wahrenbrock; Lubor Borsig; Dzung Le; Nissi Varki; Ajit Varki
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

9.  Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.

Authors:  Yuan Rong; Vladimir E Belozerov; Carol Tucker-Burden; Gang Chen; Donald L Durden; Jeffrey J Olson; Erwin G Van Meir; Nigel Mackman; Daniel J Brat
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

10.  The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancer.

Authors:  Carolyn A Staton; Andrew S A Chetwood; Iain C Cameron; Simon S Cross; Nicola J Brown; Malcolm W R Reed
Journal:  Gut       Date:  2007-06-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.